ArticleScientific reports2025
Computational investigation of Belzutifan drug delivery mechanisms using SiC nanocrystals via combined DFT and molecular dynamics approaches.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Article
- Investigating the Therapeutic Activity of CACS omega · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
This study employs density functional theory (DFT) and molecular dynamics (MD) simulations to investigate silicon carbide (SiC) nanocrystals as carriers for the anticancer drug Belzutifan. Among tested functional groups (-H, -OH, -NH₂, -COOH), carboxyl-functionalized SiC (SiC-COOH) exhibits superior drug loading capacity with an adsorption energy of -1.03 eV, representing a 25% improvement over conventional carbon-based carriers. The SiC-COOH system demonstrates exceptional stability with a formation energy of -5.42 eV/atom and a remarkably high dipole moment of 142.1 D, facilitating enhanced solubility. Electronic structure analysis reveals significant charge transfers (-0.25e) from Belzutifan to the nanocrystal, accompanied by a substantial reduction in the HOMO-LUMO gap from 5.427 eV (pristine SiC) to 3.41 eV (Belzutifan@SiC-COOH complex), indicating improved electronic coupling. MD simulations confirm the complex's stability under physiological conditions, maintaining structural integrity with root-mean-square deviation (RMSD) values below 2.5 Å throughout the 5 ps simulation. Characteristic shifts in optical spectra (200-600 nm range) and IR vibrational modes (15-40 cm⁻¹) provide clear spectroscopic signatures of successful drug adsorption. The combination of strong binding (-1.03 eV adsorption energy), maintained biocompatibility, and tunable electronic properties positions functionalized SiC nanocrystals as a promising platform for targeted Belzutifan delivery, with potential applications in photo-triggered release systems.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.